Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 6 de 6
Filter
1.
J Cardiovasc Med (Hagerstown) ; 22(5): 335-343, 2021 05 01.
Article in English | MEDLINE | ID: mdl-32941324

ABSTRACT

Demographic characteristics of patients with cardiac implantable electronic devices have significantly changed during the last few years, according to the ageing of the population and the consequent increase in the number of elderly individuals with indication for pacemaker implant and, on the other hand, to the increased number of young individuals implanted with an implantable cardioverter defibrillator for the primary prevention of sudden death. More and more often, both elderly and young patients ask the physician to deal with the device in their daily activities, which often include sport practice. This latter is advisable because of its recognized benefits on cardiovascular prevention, although there are many limitations for patients with a cardiac implantable electronic device. Hence, the need to balance the patient's request with the appropriate precautions emerging from existing evidence. The current article aims to provide an overview of the most recent data on this topic, derived from registries and observational studies. Over the years an attempt to standardize recommendations has been made, but robust evidence is still lacking. Substantial differences exist between countries based on their sports regulations. Official recommendations of European and American Scientific Societies are resumed. The future perspective is to obtain data to allow these patients a safer practice of sport activity also through technological advances in terms of device materials and programming improvement and the possibility of remote monitoring.


Subject(s)
Activities of Daily Living , Defibrillators, Implantable , Pacemaker, Artificial , Patient Preference , Sports , Arrhythmias, Cardiac/prevention & control , Death, Sudden, Cardiac/prevention & control , Defibrillators, Implantable/psychology , Defibrillators, Implantable/trends , Directive Counseling/methods , Directive Counseling/trends , Humans , Pacemaker, Artificial/psychology , Pacemaker, Artificial/trends , Sports/legislation & jurisprudence , Sports/standards , Sports/trends
2.
J Cardiovasc Med (Hagerstown) ; 21(9): 696-703, 2020 Sep.
Article in English | MEDLINE | ID: mdl-32639329

ABSTRACT

BACKGROUND: Several ECG voltage criteria have been proposed for the diagnosis of left ventricular hypertrophy (LVH). Notably, ECG criteria have been historically validated in concentric LVH but not in hypertrophic cardiomyopathy (HCM), wherein the hypertrophy pattern is typically asymmetric. OBJECTIVES: The aim of our study was to evaluate the performance of ECG voltage criteria for LVH diagnosis in the HCM population. MATERIAL AND METHODS: The electrocardiograms of 92 HCM patients and 41 sex- and age-matched controls were evaluated with the most frequently used ECG voltage criteria for LVH diagnosis. Cardiac magnetic resonance (MRI) was performed in HCM and controls in order to quantify LVH and its distribution. RESULTS: In the HCM population, the maximal diagnostic accuracy was achieved by Amplitude total and Amplitude total product criteria (58% for both), while the Cornell Voltage best performed in septal HCM (62%), the Sokolov in aVL and Gubner criteria in apical HCM (79% for both) and the Cornell Voltage and Product in anterior HCM (86% for both). All the ECG voltage criteria showed a poor correlation with left ventricular mass and maximal thickness measured by cardiac MRI. CONCLUSIONS: In our study, only a few ECG voltage criteria used for the detection of LVH in clinical practice showed an acceptable performance in the HCM population. Further studies are needed to clarify the role of ECG for LVH detection in HCM patients.


Subject(s)
Action Potentials , Cardiomyopathy, Hypertrophic/diagnosis , Electrocardiography , Heart Conduction System/physiopathology , Heart Rate , Hypertrophy, Left Ventricular/diagnosis , Adult , Aged , Cardiomyopathy, Hypertrophic/physiopathology , Female , Humans , Hypertrophy, Left Ventricular/physiopathology , Magnetic Resonance Imaging, Cine , Male , Middle Aged , Predictive Value of Tests , Reproducibility of Results , Retrospective Studies , Ventricular Function, Left , Ventricular Remodeling
3.
Minerva Cardioangiol ; 68(2): 98-109, 2020 Apr.
Article in English | MEDLINE | ID: mdl-32429628

ABSTRACT

Physical activity is worldwide recommended for its benefits on cardiovascular system. There is an increasing number of people of all ages that approach sport activity both as leisure time physical activity and as competitive sport. It is always more frequent the request even from older subjects and cardiac patients to be allowed to practice physical activity. Some problems could arise when these subjects present or develop pathologic conditions that require specific pharmacological treatment, in particular an anticoagulation therapy. This review focalizes on the management of oral anticoagulant therapy (OAT) in patients practicing sport activity, especially due to atrial fibrillation and deep vein thrombosis, which represent two highly prevalent conditions, particularly with increasing age. Official recommendations in this field may appear limiting for patients, forbidding in the majority of cases sports at risk of trauma and consequent bleeding. These recommendations still resent the heritage of the "traditional" management of OAT, mainly represented by vitamin-K antagonists (VKAs). The non-vitamin K antagonist oral anticoagulants, with their more favorable pharmacokinetic-pharmacodynamic profile compare to VKAs, may now represent an opportunity to modify the approach to sport activity in patients with an indication to OAT. This review of the literature deals with possible strategies to overcome the present limitations for OAT subjects willing to pursue a healthy lifestyle, that include sport activity, minimizing at the same time their risk of bleeding.


Subject(s)
Anticoagulants/administration & dosage , Exercise/physiology , Sports , Administration, Oral , Anticoagulants/adverse effects , Anticoagulants/pharmacokinetics , Atrial Fibrillation/drug therapy , Hemorrhage/chemically induced , Humans , Venous Thrombosis/drug therapy
4.
Curr Rheumatol Rep ; 20(12): 81, 2018 11 05.
Article in English | MEDLINE | ID: mdl-30397830

ABSTRACT

PURPOSE OF THE REVIEW: An increased prevalence of cardiovascular risk factors in rheumatoid arthritis (RA) is reported. The absolute cardiovascular risk in RA patients is higher than in the general population, and although the RA prognosis has gradually improved, premature cardiovascular (CV) mortality remains a matter of fact. The purpose of this review is to shed light on CV and metabolic involvement in RA, with the aim of defining its best management. RECENT FINDINGS: Multiple lines of evidence have revealed common mechanisms behind inflammatory and CV diseases and clarified the metabolic and CV pathways involved in RA and the effects of different pharmacological treatments. CV risk assessment should be mandatory in all RA patients, taking into account the impact of both diseases on patient's prognosis. Therefore, a multidisciplinary approach is the best management, and rheumatologists, cardiologists, and general practitioners must work together to significantly improve outcome and quality of life in RA patients. Future research could investigate the potential beneficial effects of a more aggressive pharmacological treatment of CV and metabolic risk factors.


Subject(s)
Arthritis, Rheumatoid/epidemiology , Cardiovascular Diseases/epidemiology , Metabolic Diseases/epidemiology , Comorbidity , Humans , Prevalence , Risk Assessment , Risk Factors
5.
World J Cardiol ; 8(2): 114-9, 2016 Feb 26.
Article in English | MEDLINE | ID: mdl-26981208

ABSTRACT

Anti-arrhythmic properties of n-3 polyunsaturated fatty acids, at least in part mediated by anti-oxidant, anti-inflammatory and anti-fibrotic power, have been widely proved. Effect of fish oil on atrial fibrillation, both in primary and in secondary prevention and after cardiac surgery, are controversial, mostly due to lack of homogeneity between studies but also due to individual variability in response to fatty acids administration. Inclusion of measurement of incorporation of fish oil into cell membranes, appears to be essential in future studies, to assess their antiarrhythmic effect.

6.
Eur J Cardiothorac Surg ; 47(4): 698-702, 2015 Apr.
Article in English | MEDLINE | ID: mdl-24970572

ABSTRACT

OBJECTIVES: The aim of this study was to evaluate 17-year actual clinical outcomes of patients undergoing coronary artery bypass graft (CABG) using skeletonized versus pedicled bilateral internal mammary arteries (BIMAs). METHODS: From September 1991 to June 1996, 548 consecutive patients underwent CABG for multivessel disease using BIMA. After propensity matching, 350 patients were enrolled: 175 patients with skeletonized BIMA (Group S) and 175 with pedicled BIMA (Group P). The two groups were adequately comparable. Composite end-point: deaths, new revascularization and new myocardial infarctions were defined as 'events'. RESULTS: Group S provided a higher rate of total arterial myocardial revascularization (94.3 vs 82.9%, P 0.001) with a higher average number of arterial anastomoses (3.1 ± 0.8 vs 2.7 ± 0.8, P < 0.001) and BIMA anastomoses (2.5 ± 0.3 vs 2.1 ± 0.3, P < 0.001). In Group S, the incidence of sequential grafts was higher (37.7 vs 17.7%, P < 0.001). The rate of sternal wound healing problems was lower (1.7 vs 7.4%, P = 0.010). Thirty-day mortality and morbidity were similar. The median survival time of survivors was 17.8 years (min-max = 17.0-21.5); 17.3 (17.0-18.0) in Group S vs 19.1 (18.1-21.5) in Group P, P < 0.001. Seventeen-year actual outcomes were better in Group S: deaths (8.7 vs 27.9%, P < 0.001), cardiac deaths (4.7 vs 13.4%, P = 0.005), cardiac events (10.5 vs 22.1%, P = 0.003), new revascularization (2.9 vs 8.7%, P = 0.021) and events (15.1 vs 36.1%, P < 0.001). CONCLUSIONS: Skeletonization of BIMA allows one to achieve a higher rate of arterial grafting and better outcome if compared with pedicled BIMA.


Subject(s)
Coronary Artery Bypass/methods , Coronary Artery Bypass/statistics & numerical data , Mammary Arteries/surgery , Myocardial Revascularization/methods , Myocardial Revascularization/statistics & numerical data , Aged , Coronary Artery Bypass/adverse effects , Coronary Artery Bypass/mortality , Female , Humans , Male , Middle Aged , Myocardial Revascularization/adverse effects , Myocardial Revascularization/mortality , Retrospective Studies , Treatment Outcome
SELECTION OF CITATIONS
SEARCH DETAIL
...